Date: 2015-10-13
Type of information: Private placement
Company: Prima Biomed (Australia)
Investors: Nyenburgh Investment Partners (NYIP) (The Netherlands)
Amount: €1 million
Funding type: private placement
Planned used: The proceeds from the Placement will be used to fund Prima’s IMP321 clinical trial program and provide additional working capital.
Others: * On October 13, 2015, Prima BioMed announces that it has raised €1M (approx. A$1.55M) via a placement of shares at A$0.05 per share (Placement) to Nyenburgh Investment Partners (NYIP), a specialist healthcare
investor based in the Netherlands.
Therapeutic area: Cancer - Oncology
